<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4143">
  <stage>Registered</stage>
  <submitdate>11/08/2009</submitdate>
  <approvaldate>11/08/2009</approvaldate>
  <nctid>NCT00957086</nctid>
  <trial_identification>
    <studytitle>Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head &amp; Neck Cancer</studytitle>
    <scientifictitle>Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head &amp; Neck Squamous Cell Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IHN01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Squamous Cell of Head and Neck</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nimotuzumab
Treatment: drugs - Placebo

Active Comparator: Nimotuzumab - Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab

Placebo Comparator: Placebo - Comprising Adjuvant Cisplatin, Concurrent RT and Placebo


Treatment: drugs: Nimotuzumab
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.

Treatment: drugs: Placebo
Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm</outcome>
      <timepoint>5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare the overall survival between the two arms</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the Toxicity Profile between the 2 arms</outcome>
      <timepoint>5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age should be greater than or equal to the minimum age of consent in the applicable
             country

          -  Histologically proven head and neck squamous cell cancer (excluding nasopharynx,
             salivary glands, paranasal sinuses and unknown primaries) on biopsy of the primary
             lesion or the neck mass.

          -  Resectable stage III/IV according to the AJCC/UICC staging system with no evidence of
             distant metastasis.

          -  Complete macroscopic resection.

          -  Patients should have at least one of the following pathological features for
             inclusion: pT3 or pT4 and any nodal stage (N), except T3N0 of the larynx, with
             negative resection margins, or a tumor stage of 1 or 2 with a nodal stage of 2 or 3
             and no distant metastasis (M0); patients with stage T1 or T2 and N0 or N1 who had
             unfavorable pathological findings (extranodal spread, positive resection margins,
             perineural involvement, or vascular tumor embolism) are also eligible, as are those
             with oral-cavity or oropharyngeal tumors with involved lymph nodes at level IV or V.

          -  Performance status must be ECOG 0 or 1. Patients should be able to tolerate
             chemotherapy and radiotherapy.

          -  Adequate bone marrow, renal and hepatic function:

               1. WBC&gt;3000/mm3, platelets&gt;100000/mm3

               2. Serum creatinine&lt;upper limit of normal range as per institution and calculated
                  creatinine clearance (according to the Cockcroft and Gault method) &gt;50 ml/min.

               3. SAP, SGOT&lt;2 x upper limit of normal range, bilirubin &lt;1.5 x upper limit of normal
                  range.

          -  Written informed consent.</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Histology other than SCC or its subtype.

          -  Patients with disease subsite deemed suitable for organ preservation approach, namely
             stage III/IV laryngeal or hypopharyngeal carcinoma with not more than low-volume T4
             disease; low-volume T4 disease is defined as disease not eroding into cartilage or
             extending not more than 1 cm into the base of tongue.

          -  Clinical or radiological evidence of distant metastasis.

          -  Uncontrolled comorbidities such as diabetes mellitis, hypertension, cardiac disease.

          -  Uncontrolled infection.

          -  Uncontrolled hypercalcemia.

          -  Prior history of cancer less than 5 years ago or a synchronous primary outside the
             head and neck area.

          -  Prior treatment, head and neck radiotherapy, chemotherapy or surgery (excluding
             biopsy) or anti-EGFR therapy such as cetuximab/EGFR oral tyrosine kinase inhibitor.

          -  Patients for whom compliance with follow-up is unlikely.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>710</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode> - Bedford Park</postcode>
    <postcode>VIC 3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Cuba</country>
      <state>Vedado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Alexandria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Cairo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Kerala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Trivandrum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Jakarta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Melaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Manila</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Quezon City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Riyadh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Panorama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>National Cancer Centre, Singapore</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Medical Research Council (NMRC), Singapore</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Innogene Kalbiotech Pte. Ltd</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to improve the loco-regional control rate and overall survival of
      locally advanced head and neck squamous carcinoma (HNSCC). The investigators hypothesize that
      the addition of nimotuzumab (a recombinant humanized murine immune antibody that blocks both
      epidermal growth factor (EGF) and transforming growth factor (TGF)) to the current gold
      standard of concurrent chemoradiotherapy (CCRT) (7)(8), an adjuvant setting in patients after
      resection of their locally advanced HNSCC will confer therapeutic advantage.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00957086</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>K C Soo, Prof</name>
      <address>National Cancer Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>K C Soo, Prof</name>
      <address />
      <phone>+65 64368000</phone>
      <fax />
      <email>admskc@nccs.com.sg</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>